Axovant Announced Administration of AXO-Lenti-PD, A Novel Gene Therapy for Patient’s with Parkinson’s Disease, to First Patient in Clinical Study

October 25, 2018 — Axovant announced that the first patient in a clinical study was administered dosing of AXO-Lenti-PD, which is an investigational gene therapy to treat Parkinson’s disease, that enables the expression of a set of three critical enzymes needed for end-to-end dopamine synthesis in the brain. For the full article, please visit Axovant’s website.
Read More